These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37726835)

  • 1. The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance.
    Liu A; Gao Y; Wang Q; Lin W; Ma Z; Yang X; Chen L; Xu D
    J Transl Med; 2023 Sep; 21(1):641. PubMed ID: 37726835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
    Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
    Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumor heterogeneity and clonal evolution revealed in castration-resistant prostate cancer by longitudinal genomic analysis.
    Zhang W; Wang T; Wang Y; Zhu F; Shi H; Zhang J; Wang Z; Qu M; Zhang H; Wang T; Qian Y; Yang J; Gao X; Li J
    Transl Oncol; 2022 Feb; 16():101311. PubMed ID: 34902740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
    Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P
    Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry.
    Garcia-Rodriguez J; Fernandez-Gomez JM; Cozar JM; Miñana B; Gomez-Veiga F; Rodriguez-Antolin A; ;
    Actas Urol Esp (Engl Ed); 2020 Apr; 44(3):156-163. PubMed ID: 32113829
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Alzoubi A; Al Bashir S; Smairat A; Alrawashdeh A; Haddad H; Kheirallah K
    J Med Life; 2023 Apr; 16(4):593-598. PubMed ID: 37305830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [COST ANALYSIS OF ANDROGEN DEPRIVATION THERAPY AND DRUGS FOR CASTRATION-RESISTANT PROSTATE CANCER].
    Nishizawa K; Hattahara K; Onishi H; Yoshida T
    Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):53-57. PubMed ID: 35444081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C; Abboud K
    Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
    Beltran H; Prandi D; Mosquera JM; Benelli M; Puca L; Cyrta J; Marotz C; Giannopoulou E; Chakravarthi BV; Varambally S; Tomlins SA; Nanus DM; Tagawa ST; Van Allen EM; Elemento O; Sboner A; Garraway LA; Rubin MA; Demichelis F
    Nat Med; 2016 Mar; 22(3):298-305. PubMed ID: 26855148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Begemann D; Wang Y; Yang W; Kyprianou N
    Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
    Mostaghel EA; Page ST; Lin DW; Fazli L; Coleman IM; True LD; Knudsen B; Hess DL; Nelson CC; Matsumoto AM; Bremner WJ; Gleave ME; Nelson PS
    Cancer Res; 2007 May; 67(10):5033-41. PubMed ID: 17510436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy.
    Beck J; Rouleau M; Lemire F; Neveu B; Déry M; Thériault B; Dubois G; Guérette D; Pouliot F
    Prostate; 2023 May; 83(7):670-677. PubMed ID: 36851864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
    Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent androgen deprivation therapy in advanced prostate cancer.
    Alva A; Hussain M
    Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
    Ming J; Wu Y; Han R; Xu X; Waldeck R; Hu S
    Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the duration of castration resistance predictive for sequential treatment responses in the metastatic castration-resistant prostate cancer setting?
    Dülgar Ö; Özyükseler DT; Başak M; Ay S; Tural D; Yıldırım ME; Gümüş M
    J Oncol Pharm Pract; 2021 Sep; 27(6):1388-1394. PubMed ID: 32847482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal origin and spread of metastatic prostate cancer.
    Van Etten JL; Dehm SM
    Endocr Relat Cancer; 2016 Apr; 23(4):R207-17. PubMed ID: 27000662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castration-resistance prostate cancer patients treated with docetaxel.
    Shi X; Pei X; Fan J; Liu T; Zhang D; Yang T; Wu K; He D; Li L
    Andrologia; 2021 May; 53(4):e13916. PubMed ID: 33591598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastasic Prostate Cancer: Predictive Factors of Earlier Progression to Castration-Resistance.
    Dellavedova T; Malizia E; Quinteros L; Nobile R; Minuzzi F
    Arch Esp Urol; 2022 Jun; 75(5):430-434. PubMed ID: 35983814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.